Patents by Inventor Kana Taniguchi

Kana Taniguchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070066618
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Application
    Filed: November 3, 2006
    Publication date: March 22, 2007
    Inventors: Masato Shimojo, Kana Taniguchi
  • Patent number: 7148234
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: December 12, 2006
    Assignee: Pfizer Inc.
    Inventors: Masato Shimojo, Kana Taniguchi
  • Patent number: 7141580
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5–6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5–12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl; R5 is H, C1-4 alkyl, etc.; Q2 is a 5–12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.
    Type: Grant
    Filed: February 4, 2004
    Date of Patent: November 28, 2006
    Assignee: Pfizer Inc.
    Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
  • Publication number: 20040181059
    Abstract: This invention provides a compound of the formula (I): 1
    Type: Application
    Filed: February 4, 2004
    Publication date: September 16, 2004
    Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
  • Patent number: 6710054
    Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N, and S, etc.; A is 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl; R5 is H, C1-4 alkyl; etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: March 23, 2004
    Assignee: Pfizer Inc
    Inventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
  • Publication number: 20030236260
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Application
    Filed: April 10, 2003
    Publication date: December 25, 2003
    Inventors: Masato Shimojo, Kana Taniguchi
  • Publication number: 20020107273
    Abstract: This invention provides a compound of the formula (I): 1
    Type: Application
    Filed: October 15, 2001
    Publication date: August 8, 2002
    Inventors: Kazunnari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi